Diverticulitis: New concepts and new therapies

Journal of Clinical Gastroenterology

Volumn 39, Issue 5, 2005, Pages 355-356

  Floch, Martin H ^a   White, Jonathan ^b  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NORWALK HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ANTIINFLAMMATORY AGENT; MESALAZINE; PROBIOTIC AGENT;

CROHN DISEASE; DIVERTICULITIS; EDITORIAL; ESCHERICHIA COLI; HUMAN; INTESTINE FLORA; NONHUMAN; PRIORITY JOURNAL; RECURRENT DISEASE; ULCERATIVE COLITIS;

ANTI-INFLAMMATORY AGENTS; COLITIS, ULCERATIVE; CROHN DISEASE; DIVERTICULITIS; DIVERTICULUM, COLON; DRUG THERAPY, COMBINATION; ESCHERICHIA COLI; FOLLOW-UP STUDIES; HUMANS; PROBIOTICS; TREATMENT OUTCOME;

EID: 17444389725     PISSN: 01920790     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.mcg.0000159264.27986.1f     Document Type: Editorial

References (10)

1. Peppercorn MA. The overlap of inflammatory bowel disease and diverticular disease. J Clin Gastroenterol. 2004;38(Suppl):8-10.
2. West BA, Losada M. The pathology of diverticulosis Coli. J Clin Gastroenterol. 2004;38(Suppl):11-16.
3. Floch MA, Bina I. The natural history of diverticulitis. J Clin Gastroenterol. 2004;38(Suppl):2-7.
4. Narayan R, Floch MH. Microscopic colitis as part of the natural history of diverticular disease [Abstract]. Am J Gastroenterol. 2002;97(Suppl):112.
5. Tursi A. Mesalazine for diverticular disease of the colon: a new role for an old drug. Expert Opin Pharmacother. 2005;6:69-74.
6. Trespi E, Colla C, Panizza P, et al. Therapeutic and prophylactic role of mesalazine (5-ASA) in symptomatic diverticular disease of the large intestine: 4 year follow-up results. Minerva Gastroenterol Dietol. 1999;45:245-252.
7. Giovanni A, Leandro G, Fanigliulo M, et al. Efficacy of mesalazine in the treatment of symptomatic diverticular disease. Dig Liver Dis. 2004;36(Suppl 2):189.
8. Brandimarte G, Tursi A. Rifaximin plus mesalazine followed by mesalazine alone is highly effective in obtaining remission of symptomatic uncomplicated diverticular disease. Med Sci Monit. 2004;10:170-173.
9. Tursi A, Brandimarte G, Daffina R. Long-term treatment with mesalazine and rifaximin versus rifaximin alone for patients with recurrent attacks of acute diverticulitis of the colon. Dig Liver Dis. 2002;34:510-515.
10. Frič P, Zavoral M. The effect of non-pathogenic Escherichia coli in symptomatic uncomplicated diverticular disease of the colon. Eur J Gastroenterol Hepatol. 2003;15:313-331.